Department of Radiation Oncology, University Hospital Johann Wolfgang Goethe University Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany.
German Cancer Research Center (DKFZ), Heidelberg, Germany.
Strahlenther Onkol. 2022 Jul;198(7):654-662. doi: 10.1007/s00066-022-01931-4. Epub 2022 Apr 20.
As the population ages, the incidence of rectal cancer among elderly patients is rising. Due to the risk of perioperative morbidity and mortality, alternative nonoperative treatment options have been explored in elderly and frail patients who are clinically inoperable or refuse surgery.
Here we present technical considerations and first clinical experience after treating a cohort of six rectal cancer patients (T1‑3, N0‑1, M0; UICC stage I-IIIB) with definitive external-beam radiation therapy (EBRT) followed by image-guided, endorectal high-dose-rate brachytherapy (HDR-BT). Patients were treated with 10-13 × 3 Gy EBRT followed by HDR-BT delivering 12-18 Gy in two or three fractions. Tumor response was evaluated using endoscopy and magnetic resonance imaging of the pelvis.
Median age was 84 years. All patients completed EBRT and HDR-BT without any high-grade toxicity (> grade 2). One patient experienced rectal bleeding (grade 2) after 10 weeks. Four patients (67%) demonstrated clinical complete response (cCR) or near cCR, there was one partial response, and one residual tumor and hepatic metastasis 8 weeks after HDR-BT. The median follow-up time for all six patients is 42 weeks (range 8-60 weeks). Sustained cCR without evidence of local regrowth has been achieved in all four patients with initial (n)cCR to date.
Primary EBRT combined with HDR-BT is feasible and well tolerated with promising response rates in elderly and frail rectal cancer patients. The concept could be an integral part of a highly individualized and selective nonoperative treatment offered to patients who are not suitable for or refuse surgery.
随着人口老龄化,老年患者直肠癌的发病率正在上升。由于围手术期发病率和死亡率的风险,对于临床不可手术或拒绝手术的老年和体弱患者,已经探索了替代的非手术治疗选择。
在这里,我们介绍了在接受了根治性外照射放疗(EBRT)后,对 6 例直肠癌患者(T1-3、N0-1、M0;UICC 分期 I-IIIB)进行治疗的技术考虑因素和初步临床经验,随后进行了图像引导的直肠内高剂量率近距离放疗(HDR-BT)。患者接受了 10-13×3 Gy 的 EBRT,然后接受了 HDR-BT,单次剂量为 12-18 Gy,分两次或三次进行。通过内窥镜检查和骨盆磁共振成像评估肿瘤反应。
中位年龄为 84 岁。所有患者均完成了 EBRT 和 HDR-BT,没有任何 3 级以上的毒性(>2 级)。1 例患者在 10 周后出现直肠出血(2 级)。4 例患者(67%)表现出临床完全缓解(cCR)或接近 cCR,1 例部分缓解,1 例在 HDR-BT 后 8 周时出现残留肿瘤和肝转移。所有 6 例患者的中位随访时间为 42 周(8-60 周)。到目前为止,所有 4 例初始(n)cCR 的患者均获得了持续的 cCR,且没有局部复发的迹象。
对于不适合或拒绝手术的老年和体弱直肠癌患者,EBRT 联合 HDR-BT 是可行的,且耐受性良好,具有令人鼓舞的反应率。该概念可以成为为不适合或拒绝手术的患者提供的高度个体化和选择性非手术治疗的重要组成部分。